Announcement on Abnormal Fluctuations in Stock Trading
Filed with SSE · · 3 pages · Chinese
Earlier from Sinotherapeutics
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on the Expiry of Planned Time for Shareholders with Over 5% Shares to Reduce Shares and Results of Shareholding Reduction
- Senior Management Member" -- Announcement on Completing Term Change and Election of the Board of Directors and Appointing Senior Management Members and Securities Affairs Representative, as well as Departure of Core Technical Personnel
- Announcement on Voluntary Disclosure of Obtaining the Colombian INVIMA Approval for Bupropion Hydrochloride Extended-release Tablets
- Notice on Convening the 2025 Annual General Meeting
Later from Sinotherapeutics
- Announcement on Voluntary Disclosure of Doxofylline Tablets Passing the Consistency Evaluation of Generic Drugs and the Addition of a New Specification
- Announcement on Voluntary Disclosure of Approval of Posaconazole Enteric-coated Tablets via the EU Decentralised Procedure (DCP)
- Announcement on Voluntary Disclosure of Proposed Selection in the National Centralized Drug Procurement
- Announcement on Using Certain Idle Raised Funds for Cash Management
- Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
Follow Sinotherapeutics into a list and get an email when it puts out news.
Follow Sinotherapeutics